Search

Your search keyword '"Xaplanteris, Panagiotis"' showing total 279 results
Start Over Author "Xaplanteris, Panagiotis"
279 results on '"Xaplanteris, Panagiotis"'

1. Contributors

Author

Agabiti-Rosei, Claudia, primary, Agabiti-Rosei, Enrico, additional, Agnoletti, Davide, additional, Alastruey, Jordi, additional, AlGhatrif, Majd, additional, Almada, Horacio, additional, Ángela, Sardella, additional, Argyris, Antonios, additional, Aristizabal, Dagnovar, additional, Armeni, Eleni, additional, Avolio, Alberto, additional, Badariene, Jolita, additional, Badhwar, Smriti, additional, Barbosa, Eduardo Costa Duarte, additional, Barroso, Weimar Kunz Sebba, additional, Bascetin, Rümeyza, additional, Baynard, Tracy, additional, Becerra, Carlos Ramos, additional, Bennett, Nadia, additional, Bianchini, Elisabetta, additional, Bohn, Lucimere, additional, Borghi, Claudio, additional, Bortolotto, Luiz Aparecido, additional, Boutouyrie, Pierre, additional, Bruno, Rosa Maria, additional, Burnier, Michel, additional, Butlin, Mark, additional, Calabria, Fabiana, additional, Camafort, Miguel, additional, Cavero-Redondo, Iván, additional, Challande, Pascal, additional, Chirinos, Julio A., additional, Climie, Rachel Emma, additional, Cockcroft, John, additional, Cotter, Jorge, additional, Cruickshank, J. Kennedy, additional, Cunha, Pedro Guimarães, additional, Damianaki, Aikaterini, additional, De Backer, Tine, additional, De Buyzere, Marc L., additional, De Caterina, Raffaele, additional, De Ciuceis, Carolina, additional, Debette, Stephanie, additional, Edsfeldt, Andreas, additional, Fernhall, Bo, additional, Ferreira, Isabel, additional, Fisher, Simon, additional, Forcada, Pedro, additional, S. Franklin, Stanley, additional, Garcia, Ricardo, additional, Georgiopoulos, Georgios, additional, Ghiadoni, Lorenzo, additional, Goncalves, Isabel, additional, Gottsäter, Mikael, additional, Graham, Delyth, additional, Greene, Katherine, additional, Guala, Andrea, additional, Hametner, Bernhard, additional, Hashimoto, Junichiro, additional, Hering, Dagmara, additional, Hibner, Brooks A., additional, Højlund, Kurt, additional, Hughes, Alun, additional, Ikonomidis, Ignatios, additional, Johansson, Madeleine, additional, Jordan, Jens, additional, Kario, Kazuomi, additional, Kotsis, Vasilios, additional, Kozakova, Michaela, additional, Lacolley, Patrick, additional, Lagrange, Jérémy, additional, Lakatta, Edward G., additional, Lambrinoudaki, Irene, additional, Laucyte-Cibulskiene, Agne, additional, Laurent, Stéphane, additional, Lopes, Wendell Arthur, additional, Lopez-Jaramillo, Patricio, additional, Magalhaes, Lucélia Batista Neves Cunha, additional, Magnussen, Costan G., additional, Mavraganis, Georgios, additional, Mayer, Christopher Clemens, additional, Maynard, Hannah, additional, McBride, Martin W., additional, McDonnell, Barry J., additional, McEniery, Carmel M., additional, Mota, Jorge, additional, Motl, Robert W., additional, Mozos, Ioana, additional, Muiesan, Maria Lorenza, additional, Muñoz, Ernesto Cardona, additional, Narkiewicz, Krzysztof, additional, Nemcsik, János, additional, Neves, Mario Fritsch, additional, Nilsson, Jan, additional, Nilsson, Peter M., additional, Oberhoffer-Fritz, Renate, additional, Ochoa, Juan Eugenio, additional, Okawa, Jaqueline Lyrio Bermudes, additional, Okawa, Rogério Toshiro Passos, additional, Olesen, Thomas Bastholm, additional, Oliveira, José, additional, Oliveras, Anna, additional, Hecht Olsen, Michael, additional, Ortiz, Luis Garcia, additional, Pahkala, Katja, additional, Paini, Anna, additional, Palombo, Carlo, additional, Parati, Gianfranco, additional, Park, Chloe, additional, Pavlidis, George, additional, Piani, Federica, additional, Pierce, Gary L., additional, Pizzala, Pablo G., additional, Protogerou, Athanase D., additional, Pucci, Giacomo, additional, Pupi, Luis María, additional, Pupi, Pablo María, additional, Raitakari, Olli T., additional, Rajkumar, C., additional, Ramirez, Agustín, additional, Raso, Francesco Mattace, additional, Recchia, Fabio Anastasio, additional, Regnault, Veronique, additional, Rietzschel, Ernst, additional, Rizzoni, Damiano, additional, Rodilla, Enrique, additional, Rovio, Suvi P., additional, Ryliskyte, Ligita, additional, Salvi, Paolo, additional, Sanchez, Ramiro, additional, Sáry, Javier Osvaldo, additional, Schillaci, Giuseppe, additional, Schmidt-Trucksäss, Arno, additional, Scuteri, Angelo, additional, Segers, Patrick, additional, Sharman, James, additional, Sierra, Cristina, additional, Stamatelopoulos, Kimon, additional, Steckelings, Ulrike M., additional, Stehouwer, Coen D.A., additional, Stoner, Lee, additional, Taddei, Stefano, additional, Terentes-Printzios, Dimitrios, additional, Tomiyama, Hirofumi, additional, Trivett, Cara, additional, Tsioufis, Costas, additional, Turroni, Silvia, additional, Urbina, Elaine M., additional, Van Bortel, L., additional, van de Laar, Roel J., additional, van der Heide, Frank C.T., additional, Vázquez, Susana, additional, Vishram-Nielsen, Julie, additional, Vlachopoulos, Charalambos, additional, Vlastos, Dimitrios, additional, Walker, Ashley, additional, Wang, Mingyi, additional, Weber, Thomas, additional, Xaplanteris, Panagiotis, additional, Zanoli, Luca, additional, and Zhou, Manshi, additional

Published
2024
Full Text
View/download PDF

2. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program

Author

Azizi, Michel, Sharp, Andrew S.P., Fisher, Naomi D.L., Weber, Michael A., Lobo, Melvin D., Daemen, Joost, Lurz, Philipp, Mahfoud, Felix, Schmieder, Roland E., Basile, Jan, Bloch, Michael J., Saxena, Manish, Wang, Yale, Sanghvi, Kintur, Jenkins, J. Stephen, Devireddy, Chandan, Rader, Florian, Gosse, Philippe, Claude, Lisa, Augustin, Dimitri A., McClure, Candace K., Kirtane, Ajay J., Wang, Yale, Skeik, Nedaa, Bae, Richard, McMeans, Amy, Goldman, JoAnne, Peterson, Rose, Stephen Jenkins, James, Tutor, Isabelle, Harrison, Michael, Penning, Angel, Devireddy, Chandan, Lea, Janice, Fiebach, Amanda, Merlin, Claudia, Rader, Florian, Dohad, Suhail, Tran, Anne, Bhatia, Kirin, Fisher, Naomi D.L., Sobieszczyk, Piotr, Halliday, Ian, Munson, Tay, Lindsey, Jason, Laster, Steven, Bunte, Mathew, Hart, Anthony, King, Dana, Hall, Jamie, Sanghvi, Kintur, Krathen, Courtney, Lewis, Luot, Willitts, Ashley, Todoran, Thomas, Basile, Jan, Awkar, Anthony, Palmer, Casey, Tecklenburg, Anna, Schindler, John, Pacella, John, Muldoon, Matthew, Albright, MaryJo, Nicholson, Tracy, Flack, John, Chami, Youseff, Hafiz, Abdul Moiz, Starkey, Emily, Adams, Kristal, Bernardo, Nelson, Veis, Judith, Hashim, Hayder, Singh, Suman, Whitman, Donna, Stouffer, Rick, Hinderliter, Alan, Allen, Meghan, Scholl, Tatum, Fong, Pete, Gainer, James, Crook, Sherron, Hatchcock, Ellen, Cohen, Debbie, Giri, Jay, Kobayashi, Taisei, Neubauer, Robin, Naidu, Suveeksha, Kirtane, Ajay J., Radhakrishnan, Jai, Batres, Candido, Edwards, Suzanne, Khuddus, Matheen, Zentko, Suzanne, Touchton, Abby, Roberson, Marti, Bloch, Michael J., Akinapelli, Abhilash, English, Lisa, Neumann, Bridget, Mendelsohn, Farrel, Brantley, Hutton, Cawthon, Thomas, DeRamus, Susan, Wade, Wesley, Fishman, Robert, Tuohy, Edward, LeBlanc, Jessica, McCurry, Tina, Krishnaswamy, Amar, Laffin, Luke, Bajzer, Christopher, Boros, Marilyn, Branche, Monica, Abraham, Josephine, Abraham, Anu, Stijleman, Inge, Hsi, David, Martin, Scott, Portnay, Edward, Fiebach, Maryann, Garavito, Carolina, Adams, Todd, Teklinski, Andrew, Leech, Adam, Drilling, Patrick, Tulik, Lynda, Benzuly, Keith, Paparello, James, Fintel, Dan, Ramirez, Haydee, Kats, Lauren, Huang, Paul, Biswas, Santanu, Risher, Serena, Pratt, Kristina, Ibebuogu, Uzoma, Johnson, Karen, Cushman, William, Jones, Lisa, Jackson, Leigh, Landers, David, Pasala, Tilak, Salazer, Thomas, Canino, Peter, Arakelian, Patricia, Yang, Yi-Ming, Khaliq, Asma, Weinberg, Mitchell, Abetu, Yihenew, Gulliver, Alana, Reilly, J.P., Garasic, Joseph, Chugh, Atul, Bertolet, Barry, Go, Brian, Gallapudi, Raghava, Cohn, Joel, Rogers, Kevin, Saxena, Manish, Mathur, Anthony, Jain, Ajay, Balawon, Armida, Zongo, Oliver, Topham, Christine, Sharp, Andrew, Anderson, Richard, Thompson, Elizabeth, Spiro, Nikki, Hodges, Elizabeth, Holder, Jaqueline, Ellam, Timothy, Bagnall, Alan, Jackson, Ralph, Bridgett, Victoria, Wilson, Peter, Das, Neelanjan, Doulton, Timothy, Loader, David, Hector, Gemma, Levy, Terry, Bent, Clare, Kodoth, Vivek, Horler, Stephanie, Nix, Sara, Robinson, Nicholas, Al-Janabi, Firas, Sayer, Jeremy, Ganesh Iyer, Sudha, Redman, Emily, Ramirez, Jonaifah, Padmanabhan, Sandosh, Sharif, Faisal, Alhmoudi, Aishah, Lunardi, Mattia, Coen, Eileen, Glynn, Nicola, Mahfoud, Felix, Lauder, Lucas, Kulenthiran, Saarraaken, Koch, Christina, Wachter, Angelika, Schmieder, Roland, Schmid, Axel, Kannenkeril, Dennis, Heinritz, Ulrike, Endres-Frohlich, Kerstin, Lurz, Philipp, Rommel, Karl, Fengler, Petzold, Martin, Büttner, Margit, Weil, Joachim, Agdirlioglu, Tolga, Köllner, Tanja, Stephan, Jeannine, Dagkonakis, Nikolaos, Hamann, Frank, Ettl, Ute, Petzsche, Ulrike, Reimer, Peter, Hausberg, Martin, Hinrichs, Ralf, Di Ponio-Voit, Isabella, Lutz, Matthias, Gosse, Philippe, Cremer, Antoine, Papadopoulos, Panteleimon, Gaudissard, Julie, Maire, Florent, Azizi, Michel, Sapoval, Marc, Livrozet, Marine, Regrag, Asma, Paquet, Valerie, Delsart, Pascal, Hennicaux, Justin, Sommeville, Coralie, Bertrand, Fabien, Daemen, Joost, Lafeber, Melvin, Zeijen, Victor, Ruiter, Amo, Huijskens, Elisabeth, van Ramshorst, Jan, Xaplanteris, Panagiotis, Briki, Rachid, de Hemptinne, Quentin, Pascal, Severine, Renard, Katty, Ferdinande, Bert, Iglesias, Juan F., Ehert, Georg, Gallego, Laetitia, Dobretz, Kevin, Bottone, Sylviane, Sanghvi, Kintur, Costello, Josh, Krathan, Courtney, Lewis, Luot, McElvarr, Andrew, Reilly, John, Jenkins, Stephen, Cash, Michael, Williams, Shannon, Jarvis, Maria, Fong, Pete, Laffer, Cheryl, Gainer, James, Robbins, Mark, Crook, Sherron, Maddel, Sarita, Hsi, David, Martin, Scott, Portnay, Edward, Ducey, Maryanne, Rose, Suzanne, DelMastro, Elizabeth, Bangalore, Sripal, Williams, Stephen, Cabos, Stanley, Rodriguez Alvarez, Carolina, Todoran, Thomas, Basile, Jan, Powers, Eric, Hodskins, Emily, Paladugu, Vijay, Tecklenburg, Anna, Devireddy, Chandan, Lea, Janice, Wells, Bryan, Fiebach, Amanda, Merlin, Claudia, Rader, Florian, Dohad, Suhail, Kim, Hyun-Min, Rashid, Mohammad, Abraham, Josephine, Owan, Theophilus, Abraham, Anu, Lavasani, Iran, Neilson, Hailey, Calhoun, David, McElderry, Thomas, Maddox, William, Oparil, Suzanne, Kinder, Sheila, Kirtane, Ajay J., Radhakrishnan, Jai, Batres, Candido, Edwards, Suzanne, Garasic, Joseph, Drachman, Doug, Zusman, Randy, Rosenfield, Kenneth, Do, Danny, Khuddus, Matheen, Zentko, Suzanne, O’Meara, James, Barb, Ilie, Foster, Abby, Boyette, Alice, Wang, Yale, Jay, Desmond, Skeik, Nedaa, Schwartz, Robert, Peterson, Rose, Goldman, Jo Anne, Goldman, Jessie, Ledley, Gary, Katof, Nancy, Potluri, Srinivasa, Biedermann, Scott, Ward, Jacquelyn, White, Megan, Fisher, Naomi D.L., Mauri, Laura, Sobieszczky, Piotr, Smith, Alex, Aseltine, Laura, Stouffer, Rick, Hinderliter, Alan, Pauley, Eric, Wade, Tyrone, Zidar, David, Shishehbor, Mehdi, Effron, Barry, Costa, Marco, Semenec, Terence, Bloch, Michael J., Roongsritong, Chanwit, Nelson, Priscilla, Neumann, Bridget, Cohen, Debbie, Giri, Jay, Neubauer, Robin, Vo, Thu, Chugh, Atul R., Huang, Pei-Hsiu, Jose, Powell, Flack, John, Fishman, Robert, Jones, Michael, Adams, Todd, Bajzer, Christopher, Saxena, Manish, Lobo, Melvin D., Mathur, Anthony, Jain, Ajay, Balawon, Armida, Zongo, Olivier, Levy, Terry, Bent, Clare, Beckett, David, Lakeman, Nicki, Kennard, Sarah, Sharp, Andrew, D’Souza, Richard J., Statton, Sarah, Wilkes, Lindsay, Anning, Christine, Sayer, Jeremy, Ganesh Iyer, Sudha, Robinson, Nicholas, Sevillano, Annaliza, Ocampo, Madelaine, Gerber, Robert, Faris, Mohamad, John Marshall, Andrew, Sinclair, Janet, Pepper, Hayley, Davies, Justin, Chapman, Neil, Burak, Paula, Carvelli, Paula, Jadhav, Sachin, Quinn, Jane, Christian Rump, Lars, Stegbauer, Johannes, Schimmöller, Lars, Potthoff, Sebastian, Schmid, Claudia, Roeder, Sylvia, Weil, Joachim, Hafer, Lukas, Agdirlioglu, Tolga, Köllner, Tanja, Mahfoud, Felix, Böhm, Michael, Ewen, Sebastian, Kulenthiran, Saarraaken, Wachter, Angelika, Koch, Christina, Lurz, Philipp, Fengler, Karl, Rommel, Karl-Philipp, Trautmann, Kai, Petzold, Martin, Schmieder, Roland E., Ott, Christian, Schmid, Axel, Uder, Michael, Heinritz, Ulrike, Fröhlich-Endres, Kerstin, Genth-Zotz, Sabine, Kämpfner, Denise, Grawe, Armin, Höhne, Johannes, Kaesberger, Bärbel, von zur Mühlen, Constantin, Wolf, Dennis, Welzel, Markus, Gosse, Philippe, Cremer, Antoine, Trillaud, Hervé, Papadopoulos, Panteleimon, Maire, Florent, Gaudissard, Julie, Azizi, Michel, Sapoval, Marc, Cornu, Erika, Fouassier, David, Livrozet, Marine, Lorthioir, Aurélien, Paquet, Valérie, Pathak, Atul, Honton, Benjamin, Cottin, Marianne, Petit, Frédéric, Lantelme, Pierre, Berge, Constance, Courand, Pierre-Yves, Langevin, Fatou, Delsart, Pascal, Longere, Benjamin, Ledieu, Guillaume, Pontana, François, Sommeville, Coralie, Bertrand, Fabien, Daemen, Joost, Feyz, Lida, Zeijen, Victor, Ruiter, Arno, Huyskens, Elisabeth, Blankestijn, Peter, Voskuil, Michiel, Rittersma, Zwaantina, Dolmans, Helma, Kroon, A.A., van Zwam, W.H., Vranken, Jeannique, de Haan, Claudia, Persu, Alexandre, Renkin, Jean, Maes, Frédéric, Beauloye, Christophe, Lengelé, Jean-Philippe, Huyberechts, Dominique, Bouvier, Anne, Witkowski, Adam, Januszewicz, Andrzej, Kądziela, Jacek, Prejbisj, Aleksander, Hering, Dagmara, Ciecwierz, Dariusz, Jaguszewski, Milosz J., Owczuk, Radoslaw, Ciecwierz, Dariusz, Jaguszewski, Milosz J., Wang, Yale, Jay, Desmond, Skeik, Nedaa, Schwartz, Robert, Rader, Florian, Dohad, Suhail, Victor, Ronald, Sanghvi, Kintur, Costello, Josh, Walsh, Courtney, Abraham, Josephine, Owan, Theophilus, Abraham, Anu, Fisher, Naomi D.L., Mauri, Laura, Sobieszczky, Piotr, Williams, Jonathan, Bloch, Michael J., Roongsritong, Chanwit, Todoran, Thomas, Basile, Jan, Powers, Eric, Hodskins, Emily, Fong, Pete, Laffer, Cheryl, Gainer, James, Robbins, Mark, Reilly, John, Cash, Michael, Goldman, Jessie, Aggarwal, Sandeep, Ledley, Gary, Hsi, David, Martin, Scott, Portnay, Edward, Calhoun, David, McElderry, Thomas, Maddox, William, Oparil, Suzanne, Huang, Pei-Hsiu, Jose, Powell, Khuddus, Matheen, Zentko, Suzanne, O’Meara, James, Barb, Ilie, Garasic, Joseph, Drachman, Doug, Zusman, Randy, Rosenfield, Kenneth, Devireddy, Chandan, Lea, Janice, Wells, Bryan, Stouffer, Rick, Hinderliter, Alan, Pauley, Eric, Potluri, Srinivasa, Biedermann, Scott, Bangalore, Sripal, Williams, Stephen, Zidar, David, Shishehbor, Mehdi, Effron, Barry, Costa, Marco, Kirtane, Ajay J., Radhakrishnan, Jai, Lobo, Melvin D., Mathur, Anthony, Jain, Ajay, Sayer, Jeremy, Ganesh Iyer, Sudha, Robinson, Nicholas, Ali Edroos, Sadat, Levy, Terry, Patel, Amit, Beckett, David, Bent, Clare, Davies, Justin, Chapman, Neil, Shun Shin, Matthew, Howard, James, Sharp, Andrew S.P., Joseph, Anil, D’Souza, Richard, Gerber, Robert, Faris, Mohamad, John Marshall, Andrew, Elorz, Cristina, Lurz, Philipp, Höllriegel, Robert, Fengler, Karl, Rommel, Karl-Philipp, Mahfoud, Felix, Böhm, Michael, Ewen, Sebastian, Lucic, Jelena, Schmieder, Roland E., Ott, Christian, Schmid, Axel, Uder, Michael, Rump, Christian, Stegbauer, Johannes, Kröpil, Patric, Azizi, Michel, Sapoval, Marc, Cornu, Erika, Fouassier, David, Gosse, Philippe, Cremer, Antoine, Trillaud, Hervé, Papadopoulos, Panteleimon, Pathak, Atul, Honton, Benjamin, Lantelme, Pierre, Berge, Constance, Courand, Pierre-Yves, Daemen, Joost, Feyz, Lida, Blankestijn, Peter, Voskuil, Michiel, Rittersma, Zwaantina, Kroon, A.A., van Zwam, W.H., Persu, Alexandre, and Renkin, Jean

Published
2024
Full Text
View/download PDF

3. Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk.

Author

Roffi, Marco, Landi, Antonio, Heg, Dik, Frigoli, Enrico, Chalkou, Konstantina, Chevalier, Bernard, Ijsselmuiden, Alexander J.J., Kastberg, Robert, Komiyama, Nobuyuki, Morice, Marie-Claude, Onuma, Yoshinobu, Ozaki, Yukio, Peace, Aaron, Pyxaras, Stylianos, Sganzerla, Paolo, Williams, Rupert, Xaplanteris, Panagiotis, Vranckx, Pascal, Windecker, Stephan, and Smits, Pieter C.

Abstract

Abbreviated antiplatelet therapy (APT) reduces bleeding without increasing ischemic events in largely unselected high bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI). Diabetes mellitus (DM) is associated with higher ischemic risk, and its impact on the safety and effectiveness of abbreviated APT in HBR PCI patients remains unknown. This study sought to investigate the comparative effectiveness of abbreviated (1 month) vs standard (≥3 months) APT in HBR patients with and without DM after biodegradable polymer sirolimus-eluting coronary stent implantation. This was a prespecified analysis from the MASTER DAPT (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With a Abbreviated Versus Prolonged DAPT Regimen) trial, which randomized 4,579 HBR patients (1,538 [34%] with DM) to abbreviated (n = 2,295) or standard (n = 2,284) APT. The coprimary outcomes were net adverse clinical events (NACEs; composite of all-cause death, myocardial infarction, stroke, and major bleeding), major adverse cardiac or cerebral events (MACCEs; all-cause death, myocardial infarction, and stroke), and major or clinically relevant nonmajor bleeding at 11 months. HBR patients with DM had higher risks of MACCEs (HR: 1.28; 95% CI: 1.00-1.63) and similar net adverse or bleeding events compared with nondiabetic subjects. Abbreviated compared with standard APT was associated with similar NACEs and MACCEs (P interaction = 0.47 and 0.59, respectively) and reduced major or clinically relevant nonmajor bleeding (P interaction = 0.55) irrespective of diabetes status. MACCE and NACE rates were similar, and bleeding rates were lower with abbreviated APT in patients with or without diabetes. Therefore, diabetes status did not modify the treatment effects of abbreviated vs standard APT in HBR patients after biodegradable polymer sirolimus-eluting coronary stent implantation. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With a Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020) [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Usefulness of the SAGE score to predict elevated values of brachial-ankle pulse wave velocity in Japanese subjects with hypertension

Author

Tomiyama, Hirofumi, Vlachopoulos, Charalambos, Xaplanteris, Panagiotis, Nakano, Hiroki, Shiina, Kazuki, Ishizu, Tomoko, Kohro, Takahide, Higashi, Yukihito, Takase, Bonpei, Suzuki, Toru, Yamazaki, Tsutomu, Furumoto, Tomoo, Kario, Kazuomi, Inoue, Teruo, Koba, Shinji, Takemoto, Yasuhiko, Hano, Takuzo, Sata, Masataka, Ishibashi, Yutaka, Node, Koichi, Tanaka, Atsushi, Maemura, Koji, Ohya, Yusuke, Furukawa, Taiji, Ito, Hiroshi, Ohkuma, Toshiaki, Ninomiya, Toshiharu, Chikamori, Taishiro, Yamashina, Akira, and Ueda, Shin-ichiro

Published
2020
Full Text
View/download PDF

11. DISENGAGE Registry

Author

Pellicano, Mariano, Ciccarelli, Giovanni, Xaplanteris, Panagiotis, Di Gioia, Giuseppe, Milkas, Anastasios, Colaiori, Iginio, Heyse, Alex, Van Durme, Frederik, Vanderheyden, Marc, Bartunek, Jozef, De Bruyne, Bernard, and Barbato, Emanuele

Published
2020
Full Text
View/download PDF

13. Escore SAGE em Normotensos e Pré-Hipertensos: Uma Prova de Conceito

Author

Rigonatto, Rayne Ramos Fagundes, primary, Vitorino, Priscila Valverde Oliveira, additional, Oliveira, Adriana Camargo, additional, Sousa, Ana Luiza Lima, additional, Jardim, Paulo César Brandão Veiga, additional, Cunha, Pedro Miguel Guimarães Marques, additional, Barbosa, Eduardo Costa Duarte, additional, Xaplanteris, Panagiotis, additional, Vlachopoulos, Charalambos, additional, and Barroso, Weimar Kunz Sebba, additional

Published
2023
Full Text
View/download PDF

14. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society

Author

Vlachopoulos, Charalambos, Xaplanteris, Panagiotis, Aboyans, Victor, Brodmann, Marianne, Cífková, Renata, Cosentino, Francesco, De Carlo, Marco, Gallino, Augusto, Landmesser, Ulf, Laurent, Stéphane, Lekakis, John, Mikhailidis, Dimitri P., Naka, Katerina K., Protogerou, Athanasios D., Rizzoni, Damiano, Schmidt-Trucksäss, Arno, Van Bortel, Luc, Weber, Thomas, Yamashina, Akira, Zimlichman, Reuven, Boutouyrie, Pierre, Cockcroft, John, O'Rourke, Michael, Park, Jeong Bae, Schillaci, Giuseppe, Sillesen, Henrik, and Townsend, Raymond R.

Published
2015
Full Text
View/download PDF

16. Magmaris Resorbable Magnesium Scaffold Versus Conventional Drug-Eluting Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity-Score-Matching Comparison

Author

de Hemptinne, Quentin, primary, Xaplanteris, Panagiotis, additional, Guédès, Antoine, additional, Demeure, Fabian, additional, Vandeloo, Bert, additional, Dugauquier, Christophe, additional, Picard, Fabien, additional, Warne, David W., additional, Pilgrim, Thomas, additional, Iglesias, Juan F., additional, and Bennett, Johan, additional

Published
2022
Full Text
View/download PDF

19. OCT-Guided Treatment of ST-Segment Elevation Myocardial Infarction With the Drug-Eluting Resorbable Magnesium Scaffold: The BEST-MAG Study (BElgian ST-segment Elevation Myocardial Infarction Treatment With Resorbable MAGnesium Scaffold) Versus Conventional Drug-Eluting Stents

Author

de Hemptinne, Quentin, primary, Xaplanteris, Panagiotis, additional, Guédès, Antoine, additional, Demeure, Fabian, additional, Vandeloo, Bert, additional, Dugauquier, Christophe, additional, Iglesias, Juan, additional, Warne, David W., additional, Pilgrim, Thomas, additional, and Bennett, Johan, additional

Published
2022
Full Text
View/download PDF

20. Magmaris resorbable magnesium scaffold versus conventional drug-eluting stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de cardiologie, de Hemptinne, Quentin, Xaplanteris, Panagiotis, Guedes, Antoine, Demeure, Fabian, Vandeloo, Bert, Dugauquier, Christophe, Picard, Fabien, Warne, David W, Pilgrim, Thomas, Iglesias, Juan F, Bennett, Johan, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de cardiologie, de Hemptinne, Quentin, Xaplanteris, Panagiotis, Guedes, Antoine, Demeure, Fabian, Vandeloo, Bert, Dugauquier, Christophe, Picard, Fabien, Warne, David W, Pilgrim, Thomas, Iglesias, Juan F, and Bennett, Johan

Abstract

Magmaris® (Biotronik AG, Switzerland) is the first RMS and early experience has shown promising results in stable coronary artery disease. Acute coronary syndromes have been hypothesized as a potential target group for bioresorbable scaffolds, but the efficacy and safety of RMS has not been extensively studied in ST-segment elevation myocardial infarction (STEMI). BEST-MAG is a prospective multicenter trial designed to evaluate optical coherence tomography (OCT-)guided implantation of resorbable magnesium scaffold (RMS) in STEMI. Consecutive STEMI patients fulfilling inclusion/exclusion criteria were treated with RMS following a standardized OCT-based implantation technique including systematic pre- and post-dilatation, and baseline plus final OCT imaging. The primary endpoint was a device oriented composite endpoint (DOCE) including cardiac death, target vessel myocardial infarction (TV-MI) and target lesion revascularization (TLR) within 12 months. Clinical outcomes were compared after propensity score matching (PSM) to the results of the randomized controlled BIOSTEMI trial comparing biodegradable polymer sirolimus eluting (BP-SES) and durable polymer everolimus eluting stents (DP-EES) in STEMI. Between 15th February 2019 and 25th May 2020, 30 patients were included in 5 centers. Procedural success was achieved in all cases based on OCT control with final scaffold expansion of 82 ± 11%. At twelve-months, DOCE rate was 13.3% (n = 4), including 4 cases of TLR (13.3%) and one case of TV-MI (3.3%). No cardiac death occurred, and no scaffold thrombosis (ScT) was observed. Using PSM, DOCE rates in BP-SES and DP-EES groups were 10% and 6% respectively and TLR rates were 3.3% and 0.0%. In this study, OCT-guided RMS implantation in selected STEMI patients appeared feasible but was associated with numerically higher rates of TLR as compared with conventional drug-eluting stents, although the limited number of patients included in this analysis does not allow drawing statis

Published
2022

21. Bioresorbable coronary scaffolds in the treatment of acute myocardial infarction.

Author

Unger, Philippe, Xaplanteris, Panagiotis, McEntee, Kathleen, Casado Arroyo, Ruben, Van De Borne, Philippe, Wauthy, Pierre, Kefer, Joelle, Varenne, Olivier, de Hemptinne, Quentin, Unger, Philippe, Xaplanteris, Panagiotis, McEntee, Kathleen, Casado Arroyo, Ruben, Van De Borne, Philippe, Wauthy, Pierre, Kefer, Joelle, Varenne, Olivier, and de Hemptinne, Quentin

Abstract

Bioresorbable coronary scaffolds (BRS) were developed to overcome limitation of current drug-eluting stents (DES). This thesis gathers clinical and laboratory research regarding BRS implantation in the treatment of acute myocardial infarction., Doctorat en Sciences médicales (Médecine), info:eu-repo/semantics/nonPublished

Published
2022

24. A SAGE score cutoff that predicts high-pulse wave velocity as measured by oscillometric devices in Brazilian hypertensive patients

Author

Oliveira, Adriana Camargo Sebba Barroso, Weimar Kunz de Oliveira Vitorino, Priscila Valverde Lima Sousa, Ana Luiza Fagundes, Rayne Ramos de Deus, Gilcimar Divino Guimaraes, Gilberto Campos and Barbosa, Eduardo Xaplanteris, Panagiotis Vlachopoulos, Charalambos

Abstract

We aimed to identify the optimal cutoff SAGE score for Brazilian hypertensive patients who had their pulse wave velocity (PWV) measured with oscillometric devices. A retrospective analysis of patients who underwent central blood pressure measurement using a validated oscillometric device, the Mobil-O-Graph (R) (IEM, Stolberg, Germany), between 2012 and 2019 was performed. Patients with arterial hypertension and available data on all SAGE parameters were selected. An ROC curve was constructed using the Youden index to define the best score to identify patients at high risk for high PWV. A total of 837 patients met the criteria for SAGE and diagnosis of hypertension. The median age was 59.0 years (interquartile range [IQR]: 47.0-68.0), and 50.7% of the patients were women. The following comorbidities and conditions were present: dyslipidemia (37.4%), diabetes (20.7%), a body mass index score >= 30 kg/m(2) (36.6%), use of antihypertensive drugs (69.5%), and smoking (18.3%). The median peripheral blood pressure was 128 mmHg (IQR: 117-138 mmHg) for systolic and 81 mmHg (IQR: 73-90 mmHg) for diastolic blood pressure. The median PWV was 8.3 m/s (7.1-9.8 m/s), and the prevalence of high PWV (>= 10 m/s) was 22.9% (192 patients). A cutoff SAGE score >= 8 was effective at identifying a high risk of PWV >= 10 m/s, achieving 67.19% sensitivity (95% CI: 60.1-73.8) and 93.95% specificity (95% CI: 91.8-95.7). With this cutoff point, 1 out of every 5 treated hypertensive patients would be referred for a PWV measurement. A SAGE score of >= 8 identified Brazilian hypertensive patients with a high risk of future cardiovascular events (PWV >= 10 m/s).

Published
2022

25. CRT-100.41 OCT-Guided Treatment of ST-Segment Elevation Myocardial Infarction With the Drug-Eluting Resorbable Magnesium Scaffold: The BEST-MAG Study (BElgian ST-segment Elevation Myocardial Infarction Treatment With Resorbable MAGnesium Scaffold) Versus Conventional Drug-Eluting Stents

Author

de Hemptinne, Quentin, primary, Xaplanteris, Panagiotis, additional, Guédès, Antoine, additional, Demeure, Fabian, additional, Vandeloo, Bert, additional, Dugauquier, Christophe, additional, Iglesias, Juan, additional, Warne, David W., additional, Pilgrim, Thomas, additional, and Bennett, Johan, additional

Published
2022
Full Text
View/download PDF

28. List of Contributors

Author

Agabiti-Rosei, Enrico, primary, de Backer, Tine, additional, Bortel, Luc van, additional, Boutouyrie, Pierre, additional, Burnier, Michel, additional, Caulfield, Mark, additional, Challande, Pascal, additional, Cunha, Pedro G., additional, Debette, Stephanie, additional, Edsfeldt, Andreas, additional, Ferreira, Isabel, additional, Franklin, Stanley S., additional, Fyhrquist, Frej, additional, Georgianos, Panagiotis I., additional, Gonçalves, Isabel, additional, Hering, Dagmara, additional, Jordan, Jens, additional, Kotsis, Vasilios, additional, Kozakova, Michaela, additional, van de Laar, Roel J., additional, Lacolley, Patrick, additional, Lagrange, Jérémy, additional, Lakatta, Edward G., additional, Lambrinoudaki, Irene, additional, Laurent, Stéphane, additional, Lu, Yimin, additional, McEniery, Carmel M., additional, Narkiewicz, Krzysztof, additional, Nilsson, Jan, additional, Nilsson, Peter M., additional, Ochoa, Juan E., additional, Olsen, Michael H., additional, Östgren, Carl J., additional, Palombo, Carlo, additional, Parati, Gianfranco, additional, Regnault, Veronique, additional, Ren, Meixia, additional, Rietzschel, Ernst, additional, Rizzoni, Damiano, additional, Salvi, Paolo, additional, Sarafidis, Pantelis A., additional, Schillaci, Giuseppe, additional, Schmidt-Truksäss, Arno, additional, Scuteri, Angelo, additional, Segers, Patrick, additional, Sehestedt, Thomas, additional, Shukla, Shweta, additional, Sønder, Trine K., additional, Steckelings, Ulrike M., additional, Stehouwer, Coen D.A., additional, Tsioufis, Costas, additional, Vlachopoulos, Charalambos, additional, Wang, Mingyi, additional, Weber, Thomas, additional, Witkowska, Kate, additional, and Xaplanteris, Panagiotis, additional

Published
2015
Full Text
View/download PDF

29. A SAGE score cutoff that predicts high-pulse wave velocity as measured by oscillometric devices in Brazilian hypertensive patients

Author

Oliveira, Adriana Camargo, primary, Barroso, Weimar Kunz Sebba, additional, de Oliveira Vitorino, Priscila Valverde, additional, Sousa, Ana Luiza Lima, additional, Fagundes, Rayne Ramos, additional, de Deus, Gilcimar Divino, additional, Guimarães, Gilberto Campos, additional, Barbosa, Eduardo, additional, Xaplanteris, Panagiotis, additional, and Vlachopoulos, Charalambos, additional

Published
2021
Full Text
View/download PDF

34. Guiding Myocardial Revascularization by Algorithmic Interpretation of FFR Pullback Curves: A Proof of Concept Study

Author

Argacha, Jean-François, Decamp, Jean, Vandeloo, Bert, Babin, Danilo, Lochy, Stijn, Van den Bussche, Karen, de Hemptinne, Quentin, Xaplanteris, Panagiotis, Magne, Julien, Segers, Patrick, Cosyns, Bernard, Argacha, Jean-François, Decamp, Jean, Vandeloo, Bert, Babin, Danilo, Lochy, Stijn, Van den Bussche, Karen, de Hemptinne, Quentin, Xaplanteris, Panagiotis, Magne, Julien, Segers, Patrick, and Cosyns, Bernard

Abstract

Background: Coronary artery disease distribution along the vessel is a main determinant of FFR improvement after PCI. Identifying focal from diffuse disease from visual inspections of coronary angiogram (CA) and FFR pullback (FFR-PB) are operator-dependent. Computer science may standardize interpretations of such curves. Methods: A virtual stenting algorithm (VSA) was developed to perform an automated FFR-PB curve analysis. A survey analysis of the evaluations of 39 vessels with intermediate disease on CA and a distal FFR <0.8, rated by 5 interventional cardiologists, was performed. Vessel disease distribution and PCI strategy were successively rated based on CA and distal FFR (CA); CA and FFR-PB curve (CA/FFR-PB); and CA and VSA (CA/VSA). Inter-rater reliability was assessed using Fleiss kappa and an agreement analysis of CA/VSA rating with both algorithmic and human evaluation (operator) was performed. We hypothesize that VSA would increase rater agreement in interpretation of epicardial disease distribution and subsequent evaluation of PCI eligibility. Results: Inter-rater reliability in vessel disease assessment by CA, CA/FFR-PB, and CA/VSA were respectively, 0.32 (95% CI: 0.17–0.47), 0.38 (95% CI: 0.23–0.53), and 0.4 (95% CI: 0.25–0.55). The raters' overall agreement in vessel disease distribution and PCI eligibility was higher with the VSA than with the operator (respectively, 67 vs. 42%, and 80 vs. 70%, both p < 0.05). Compared to CA/FFR-PB, CA/VSA induced more reclassification toward a focal disease (92 vs. 56.2%, p < 0.01) with a trend toward more reclassification as eligible for PCI (70.6 vs. 33%, p = 0.06). Change in PCI strategy did not differ between CA/FFR-PB and CA/VSA (23.6 vs. 28.5%, p = 0.38). Conclusions: VSA is a new program to facilitate and standardize the FFR pullback curves analysis. When expert reviewers integrate VSA data, their assessments are less variable which might help to standardize PCI eligibility and strategy evaluations. Clinical, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2021

35. SAGE SCORE THAT PREDICTS HIGH PWV APPLIED TO LATIN AMERICAN HYPERTENSIVE PATIENTS EVALUATED WITH OSCIILOMETRIC DEVICES

Author

Oliveira, Adriana Camargo, primary, Barroso, Weimar Kunz Sebba, additional, Vitorino, Priscila Valverde O., additional, Sousa, Ana Luiza Lima, additional, Fagundes, Rayne Ramos, additional, Guimarães, Gilberto Campos, additional, De Deus, Gilcimar Divino, additional, Barbosa, Eduardo, additional, Xaplanteris, Panagiotis, additional, and Vlachopoulos, Charalambos, additional

Published
2021
Full Text
View/download PDF

39. Guiding Myocardial Revascularization by Algorithmic Interpretation of FFR Pullback Curves: A Proof of Concept Study

Author

Argacha, Jean-François, primary, Decamp, Jean, additional, Vandeloo, Bert, additional, Babin, Danilo, additional, Lochy, Stijn, additional, Van den Bussche, Karen, additional, de Hemptinne, Quentin, additional, Xaplanteris, Panagiotis, additional, Magne, Julien, additional, Segers, Patrick, additional, and Cosyns, Bernard, additional

Published
2021
Full Text
View/download PDF

41. Global Fractional Flow Reserve Value Predicts 5‐Year Outcomes in Patients With Coronary Atherosclerosis But Without Ischemia

Author

Fournier, Stephane, primary, Collet, Carlos, additional, Xaplanteris, Panagiotis, additional, Zimmermann, Frederik M., additional, Toth, Gabor G., additional, Tonino, Pim A. L., additional, Pijls, Nico H. J., additional, Colaiori, Iginio, additional, Di Gioia, Giuseppe, additional, Barbato, Emanuele, additional, Jüni, Peter, additional, Fearon, William F., additional, and De Bruyne, Bernard, additional

Published
2020
Full Text
View/download PDF

42. Procedural microvascular activation in long lesions treated with bioresorbable vascular scaffolds or everolimus-eluting stents: the PROACTIVE trial

Author

Pellicano, Mariano, primary, Di Gioia, Giuseppe, additional, Ciccarelli, Giovanni, additional, Xaplanteris, Panagiotis, additional, Delrue, Leen, additional, Toth, Gabor G., additional, Van Durme, Frederik, additional, Heyse, Alex, additional, Wyffels, Eric, additional, Vanderheyden, Marc, additional, Bartunek, Jozef, additional, De Bruyne, Bernard, additional, and Barbato, Emanuele, additional

Published
2020
Full Text
View/download PDF

45. Association of Estimated Pulse Wave Velocity With Survival

Author

Vlachopoulos, Charalambos, Terentes-Printzios, Dimitrios, Laurent, Stephane, Nilsson, Peter M., Protogerou, Athanase D., Aznaouridis, Konstatinos, Xaplanteris, Panagiotis, Koutagiar, Iosif, Tomiyama, Hirofumi, Yamashina, Akira, Sfikakis, Petros P., and Tousoulis, Dimitrios

Subjects
Aged, 80 and over, Male, Survival, Research, Cardiology, Blood Pressure, Middle Aged, Pulse Wave Analysis, Online Only, Vascular Stiffness, Risk Factors, Cause of Death, Hypertension, Humans, Female, Antihypertensive Agents, Original Investigation, Aged, Proportional Hazards Models, Randomized Controlled Trials as Topic
Abstract

Key Points Question Do estimated markers of aortic stiffness, such as estimated pulse wave velocity and their change with time, predict cardiovascular events in individuals with hypertension? Findings The results of this post hoc analysis of the randomized Systolic Blood Pressure Intervention Trial (SPRINT) support an incremental predictive role of estimated pulse wave velocity with outcomes beyond Framingham Risk Score. Individuals whose estimated pulse wave velocity responded to 1 year of antihypertensive treatment demonstrated a 42% lower risk of death compared with nonresponders independent of systolic blood pressure reduction in the standard treatment group of the Systolic Blood Pressure Intervention Trial. Meaning Aortic stiffness could be used in individuals with hypertension to assess risk; it could be used also as a therapeutic target to assist patient management and improve prognosis., Importance Aortic stiffness, as assessed by carotid-femoral pulse wave velocity, is an independent predictor of future events in individuals with hypertension. Recent data suggest a predictive role of estimated pulse wave velocity (ePWV) calculated by previously published equations using age and blood pressure in future events in individuals with hypertension. Objective To investigate whether ePWV and its response to treatment predict survival in the Systolic Blood Pressure Intervention Trial (SPRINT). Design, Setting, and Participants This exploratory, hypothesis-generating, post hoc secondary analysis conducted from October 1, 2018, to August 31, 2019, examined data from 9361 participants in SPRINT and calculated ePWV at baseline and at 12 months. Adjusted hazard ratios (HRs) with 95% CIs of ePWV per 1 SD were estimated using Cox proportional hazards regression models. A total of 8450 patients were assigned to 4 groups according to their treatment allocation and their response in ePWV after 12 months. Interventions Participants were assigned a systolic blood pressure target of less than 120 mm Hg (intensive treatment) or less than 140 mm Hg (standard treatment). Main Outcomes and Measures The primary composite cardiovascular outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. Results In the SPRINT population (3332 women and 6029 men; mean [SD] age, 67.9 [9.4] years), ePWV predicted the primary outcome (HR, 1.30 [95% CI, 1.17-1.43]; P, This secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) investigates whether aortic stiffness, as assessed by estimated pulse wave velocity, and its response to treatment are associated with survival in individuals with hypertension.

Published
2019

46. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data

Author

Zimmermann, Frederik M., Omerovic, Elmir, Fournier, Stephane, Kelbæk, Henning, Johnson, Nils P., Rothenbühler, Martina, Xaplanteris, Panagiotis, Abdel-Wahab, Mohamed, Barbato, Emanuele, Høfsten, Dan Eik, Tonino, Pim A.L., Boxma-de Klerk, Bianca M., Fearon, William F., Køber, Lars, Smits, Pieter C., de Bruyne, Bernard, Pijls, Nico H.J., Jüni, Peter, Engstrøm, Thomas, Zimmermann, Frederik M., Omerovic, Elmir, Fournier, Stephane, Kelbæk, Henning, Johnson, Nils P., Rothenbühler, Martina, Xaplanteris, Panagiotis, Abdel-Wahab, Mohamed, Barbato, Emanuele, Høfsten, Dan Eik, Tonino, Pim A.L., Boxma-de Klerk, Bianca M., Fearon, William F., Køber, Lars, Smits, Pieter C., de Bruyne, Bernard, Pijls, Nico H.J., Jüni, Peter, and Engstrøm, Thomas

Abstract

Aims To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with contemporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy in patients with stable coronary lesions. Methods and results We performed a systematic review and meta-Analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 randomly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12-60months), a reduction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy (hazard ratio 0.72, 95% confidence interval 0.54-0.96; P= 0.02). The difference between groups was driven by MI. Conclusion In this IPD meta-Analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a decreased risk of MI.

Published
2019

47. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions:meta-analysis of individual patient data

Author

Zimmermann, Frederik M, Omerovic, Elmir, Fournier, Stephane, Kelbæk, Henning, Johnson, Nils P, Rothenbühler, Martina, Xaplanteris, Panagiotis, Abdel-Wahab, Mohamed, Barbato, Emanuele, Høfsten, Dan Eik, Tonino, Pim A L, Boxma-de Klerk, Bianca M, Fearon, William F, Køber, Lars, Smits, Pieter C, De Bruyne, Bernard, Pijls, Nico H J, Jüni, Peter, Engstrøm, Thomas, Zimmermann, Frederik M, Omerovic, Elmir, Fournier, Stephane, Kelbæk, Henning, Johnson, Nils P, Rothenbühler, Martina, Xaplanteris, Panagiotis, Abdel-Wahab, Mohamed, Barbato, Emanuele, Høfsten, Dan Eik, Tonino, Pim A L, Boxma-de Klerk, Bianca M, Fearon, William F, Køber, Lars, Smits, Pieter C, De Bruyne, Bernard, Pijls, Nico H J, Jüni, Peter, and Engstrøm, Thomas

Abstract

Aims: To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with contemporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy in patients with stable coronary lesions.Methods and results: We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 randomly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12-60 months), a reduction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy (hazard ratio 0.72, 95% confidence interval 0.54-0.96; P = 0.02). The difference between groups was driven by MI.Conclusion: In this IPD meta-analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a decreased risk of MI.

Published
2019

48. Angiography versus Hemodynamics to Predict the Natural History of Coronary Stenoses: A FAME 2-Substudy

Author

Ciccarelli, Giovanni, Barbato, Emanuele, Toth, Gabor G, Gahl, Brigitta, Xaplanteris, Panagiotis, Fournier, Stephane, Milkas, Anastasios, Bartunek, Jozef, Vanderheyden, Marc, Pijls, Nico, Tonino, Pim, Fearon, William F, Jüni, Peter, and De Bruyne, Bernard

Subjects
610 Medicine & health
Abstract

Among patients with documented stable coronary artery disease (CAD) and in whom no revascularization was performed, we compared the respective values of angiographic diameter stenosis (DS) and of fractional flow reserve (FFR) in predicting natural history.-The present analysis included the 607 patients from the Fractional flow reserve versus angiography in multivessel evaluation 2 (FAME 2) trial in whom no revascularization was performed. FFR varied from 0.20 to 1.00 (average 0.74 ± 0.16) and DS (by QCA) varied from 8% to 98% (average 53 ± 15). The primary end point, defined as VOCE (Vessel oriented clinical endpoint) at 2 years, was a composite of prospectively adjudicated cardiac death, vessel-related myocardial infarction, vessel-related urgent and not urgent revascularization. The stenoses were divided into 4 groups according to FFR and %DS values: Positive Concordance (PC: FFR≤0.80; DS≥50%); Negative Concordance (NC: FFR>0.80; DS0.80; DS≥50%).-The rate of VOCE was highest in the PC group (Log Rank: X=80.96; p=0.001), and lowest in the NC group. The rate of VOCE was higher in the PM group than in the NM group (H.R. 0.38, 95% C.I. 0.21 - 0.67; p=0.001). There was no significant difference in VOCE between the PC and the PM (both groups with FFR≤0.80, H.R. 0.77, 95% C.I. 0.57 - 1.09; p=0.149) and no significant difference in rate of VOCE between the NM and NC (both groups with FFR>0.80, H.R. 1.89, 95% C.I. 0.96 - 3.74; p=0.067).-In patients with stable coronary disease, physiology (FFR) is a more important determinant of the natural history of coronary stenoses than anatomy (DS).-URL: https://clinicaltrials.gov Unique Identifier: NCT01132495.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results